Versionen im Vergleich

Schlüssel

  • Diese Zeile wurde hinzugefügt.
  • Diese Zeile wurde entfernt.
  • Formatierung wurde geändert.

...

Indeed, the question of verification hovers over Raoult’s clinical trial on the effects of hydroxychloroquine on the novel coronavirus. Combining a regimen of Plaquenil —the commercial name of hydroxychloroquine—and hydroxychloroquine — and an antibiotic, Raoult treated 24 patients at IHU in early March who had tested positive for COVID-19.  After six days, the virus had
vacated had vacated the bodies of three-quarters of those same patients. On March 16, Raoult announced the results not in a scientific journal but in a YouTube video, in which he declared the jig was up for the virus. Predictably, his self-proclaimed victory then ignited the hysteria that has since swept the world and reached as far as the Oval Office.

In France, pharmacies have been overwhelmed by demands for Plaquenil, leading one pharmacist quoted by Le Monde to exclaim: “Perhaps Raoult is right, but instead of taking
the time to carry out a serious study, he has given us two months of theatrics.” Critics argue that not only were there too few subjects in the chloroquine study, but that some of them dropped out during the trial, potentially skewing the results. In addition, Raoult has not released the raw data from the trial, which, remarkably, was not double-blinded.  According to Dominique Costagliola, chief epidemiologist at the Pasteur Institute, the trial was so slapdash that “it is impossible to interpret the described result as being
attributable being attributable to the hydroxychloroquine treatment.”

...